background
respiratori
syncyti
viru
rsv
pneumonia
hematopoiet
cell
transplant
hct
associ
sever
morbid
although
rsv
rna
detect
serum
patient
rsv
lower
respiratori
diseas
lrd
hct
associ
clinic
outcom
well
establish
multivari
model
addit
role
antivir
treatment
hct
recipi
previous
analyz
multivari
model
method
retrospect
identifi
hct
recipi
virolog
confirm
rsv
lrd
test
store
plasmaserum
sampl
quantit
revers
transcript
polymeras
chain
reaction
rsv
rna
risk
factor
rsv
rna
detect
impact
rsv
rna
serum
antivir
therapi
outcom
analyz
use
multivari
cox
model
result
rsv
rna
detect
plasma
serum
patient
median
day
follow
hct
day
follow
lrd
multivari
model
neutropenia
monocytopenia
thrombocytopenia
mechan
ventil
increas
risk
plasmaserum
rsv
rna
detect
lymphopenia
steroid
use
rsv
rna
detect
increas
risk
overal
mortal
multivari
model
adjust
hazard
ratio
ahr
p
wherea
treatment
aerosol
ribavirin
decreas
risk
overal
mortal
pulmonari
death
ahr
p
ahr
p
respect
conclus
rsv
rna
detect
plasma
serum
may
marker
lung
injuri
poor
outcom
hct
recipi
rsv
lrd
treatment
aerosol
ribavirin
appear
protect
overal
pulmonari
mortal
limit
small
number
patient
account
multipl
risk
factor
diseas
sever
random
trial
examin
ribavirin
treatment
rsv
lrd
report
although
small
random
trial
examin
use
preemptiv
therapi
cost
difficulti
drug
administr
also
contribut
controversi
use
ribavirin
identifi
biolog
marker
rsv
diseas
sever
poor
outcom
import
goal
may
allow
improv
therapeut
intervent
although
clear
presenc
viral
nucleic
acid
blood
relev
virus
cytomegaloviru
adenoviru
role
less
clear
respiratori
virus
sever
studi
describ
presenc
viral
nucleic
acid
serum
whole
blood
peripher
blood
monocyt
cell
patient
infect
respiratori
virus
includ
sever
acut
respiratori
syndrom
coronaviru
influenza
viru
avian
influenza
viru
rhinoviru
rsv
suggest
correl
diseas
sever
poor
outcom
recent
evalu
serum
influenza
rna
hct
recipi
found
influenza
rna
detect
associ
hypoxemia
respiratori
failur
increas
overal
influenzarel
death
initi
studi
center
report
rsv
rna
serum
detect
may
associ
poor
outcom
formal
risk
factor
outcom
analys
lack
purpos
retrospect
studi
examin
associ
plasma
serum
rsv
rna
detect
diseas
outcom
hct
recipi
rsv
lrd
addit
evalu
clinic
virolog
factor
associ
outcom
larg
cohort
allow
analysi
use
multivari
model
hct
patient
virolog
confirm
rsv
lrd
januari
april
includ
studi
clinic
data
collect
databas
supplement
review
medic
record
studi
approv
institut
review
board
fred
hutchinson
cancer
research
center
subject
sign
inform
consent
permit
use
data
store
sampl
research
rsv
lrd
defin
rsv
detect
bronchoalveolar
lavag
bal
lung
biopsi
autopsi
specimen
associ
lower
respiratori
tract
clinic
symptom
andor
radiograph
chang
day
rsv
lrd
diagnosi
defin
date
rsv
detect
lower
tract
specimen
virolog
confirm
obtain
direct
fluoresc
antibodi
shell
vial
centrifug
convent
viral
cultur
lower
respiratori
tract
sampl
patient
also
rsv
detect
revers
transcript
polymeras
chain
reaction
rtpcr
store
serum
plasma
sampl
avail
subset
patient
weekli
plasma
serum
sampl
collect
within
week
diagnosi
lrd
test
rsv
rna
realtim
rtpcr
serum
plasma
frozen
thaw
extract
duplic
total
nucleic
acid
isol
specimen
qiaamp
viral
rna
mini
kit
qiagen
analyz
presenc
rsv
rsv
b
viral
rna
quantit
realtim
rtpcr
assay
target
rsv
matrix
gene
rtpcr
assay
perform
duplic
assess
low
level
viral
rna
optim
detect
thu
total
rtpcr
result
obtain
specimen
ensur
neg
result
due
poor
nucleic
acid
extract
inhibit
pcr
assay
copi
per
reaction
specimen
process
control
ad
lysi
buffer
extract
neg
sampl
evid
amplif
control
one
lowposit
control
contain
copi
per
reaction
rsv
neg
control
consist
cultur
uninfect
human
epitheli
cell
process
batch
patient
specimen
assay
reliabl
detect
viral
copi
per
reaction
provid
sensit
copiesml
nucleic
acid
specimen
ad
per
reaction
pcr
assay
perform
accord
standard
colleg
american
pathologist
laboratori
pass
profici
test
viral
diagnost
patient
analyz
base
first
episod
rsv
lrd
probabl
overal
surviv
estim
use
kaplanmei
method
probabl
mortal
due
respiratori
failur
pulmonari
death
estim
cumul
incid
curv
death
reason
compet
risk
logrank
test
use
compar
mortal
curv
subgroup
cox
proport
hazard
model
use
evalu
unadjust
adjust
hazard
ratio
hr
rsv
rna
detect
overal
mortal
pulmonari
death
day
day
follow
rsv
lrd
poisson
regress
use
evalu
unadjust
adjust
rel
risk
rr
respiratori
failur
defin
requir
mechan
ventil
covari
evalu
candid
risk
factor
inclus
multivari
model
list
tabl
variabl
p
univari
analysi
candid
multivari
model
model
format
risk
factor
interest
select
priori
factor
signific
univari
model
p
ad
one
one
factor
evalu
model
present
signific
confound
variabl
given
extend
studi
period
associ
chang
transplant
practic
year
transplant
evalu
time
period
well
oral
dose
load
dose
mgkg
follow
mg
everi
hour
day
mg
everi
hour
day
oral
n
intraven
n
h
current
practic
guidelin
center
involv
treatment
aerosol
ribavirin
patient
rsv
lrd
dose
g
singl
dose
hour
g
three
time
day
hour
ten
patient
also
receiv
palivizumab
patient
also
receiv
ivig
continu
timedepend
steroid
use
mechan
ventil
includ
model
rsv
rna
detect
treatment
ribavirin
oxygen
requir
diagnosi
cell
sourc
includ
model
overal
mortal
treatment
ribavirin
oxygen
requir
diagnosi
includ
model
pulmonari
death
oxygen
requir
diagnosi
presenc
rsv
rna
includ
model
respiratori
failur
twosid
p
valu
consid
statist
signific
separ
multivari
model
use
minim
number
covari
per
model
due
limit
number
outcom
event
statist
analys
perform
use
sa
window
sa
institut
inc
cari
north
carolina
identifi
patient
rsv
lrd
januari
april
characterist
cohort
outlin
tabl
median
time
lrd
hct
day
rang
day
among
patient
urd
prior
lrd
n
median
durat
urd
lrd
diagnos
day
rang
day
twentysix
patient
receiv
antivir
therapi
prior
develop
rsv
lrd
antivir
treatment
lrd
initi
median
day
rang
day
follow
lrd
diagnosi
patient
rsv
lrd
serum
sampl
avail
test
supplementari
figur
patient
sampl
avail
serum
test
repres
entir
cohort
sex
variabl
signific
variat
group
p
tabl
total
sampl
test
rsv
rna
averag
sampl
test
per
patient
rang
figur
median
number
posit
sampl
per
patient
rang
median
maximum
rna
load
among
posit
result
log
copiesml
rang
log
copi
ml
eleven
posit
sampl
posit
extract
aliquot
median
viral
load
sampl
posit
duplic
statist
higher
median
viral
load
singl
posit
sampl
vs
log
copiesml
p
twentyfour
patient
rsv
rna
detect
receiv
antivir
therapi
system
ribavirin
aerosol
ribavirin
patient
rsv
rna
detect
n
twice
n
cours
antivir
therapi
one
patient
posit
sampl
therapi
day
start
ribavirin
figur
univari
analysi
treatment
ribavirin
steroid
use
mgkg
mechan
ventil
time
diagnosi
leukopenia
neutropenia
monocytopenia
thrombocytopenia
associ
increas
risk
rsv
rna
detect
patient
serum
sampl
avail
lymphopenia
significantli
associ
increas
risk
tabl
rsv
rna
detect
patient
profound
leukopenia
white
blood
cell
wbc
count
l
compar
patient
wbc
count
cellsl
hr
confid
interv
ci
p
multivari
model
adjust
steroid
use
either
lymphopenia
neutropenia
monocytopenia
thrombocytopenia
mechan
oral
dose
load
dose
mgkg
follow
mg
everi
hour
day
mg
everi
hour
day
current
practic
guidelin
center
involv
treatment
aerosol
ribavirin
patient
rsv
lrd
dose
g
singl
dose
hour
g
three
time
day
hour
e
acut
gvhd
defin
previous
describ
f
ivig
administ
discret
attend
physician
ventil
consist
show
associ
rsv
rna
detect
neutropenia
monocytopenia
sever
thrombocytopenia
platelet
count
cellsl
also
show
increas
risk
rsv
rna
detect
tabl
bal
viral
load
avail
patient
serum
test
rsv
rna
among
patient
bal
viral
load
median
copiesml
associ
increas
risk
serum
rsv
rna
detect
hr
ci
p
univari
analysi
multivari
analysi
could
perform
due
limit
number
subject
event
among
patient
serum
avail
test
rsv
rna
detect
evalu
timedepend
manner
univari
multivari
model
detect
rsv
rna
statist
signific
risk
factor
death
day
follow
rsv
lrd
multipl
model
adjust
ribavirin
treatment
plu
covari
eg
adjust
hr
ahr
ci
p
adjust
transplant
year
except
model
includ
oxygen
use
figur
model
pulmonari
death
statist
signific
reach
patient
rsv
rna
detect
die
patient
detect
rsv
rna
sampl
die
compar
patient
peak
serum
viral
load
vs
median
adjust
variabl
higher
rsv
viral
load
associ
increas
risk
overal
death
figur
addit
compar
effect
vs
posit
rsv
rna
detect
result
mortal
see
signific
chang
hr
data
shown
univari
analysi
rsv
rna
detect
associ
increas
risk
respiratori
failur
rr
ci
p
multivari
model
perform
adjust
oxygen
use
covari
time
copathogen
wbc
count
platelet
count
day
ltd
transplant
age
transplant
condit
regimen
effect
rsv
rna
detect
longer
signific
data
shown
effect
rsv
rna
detect
length
hospit
evalu
compar
day
aliv
hospit
within
first
day
follow
diagnosi
ltd
patient
rsv
rna
detect
ltd
diagnosi
n
median
number
day
rang
wherea
median
number
day
rang
patient
without
rsv
rna
detect
p
adjust
oxygen
use
rsv
rna
detect
remain
signific
factor
affect
day
aliv
hospit
mean
differ
day
ci
p
among
patient
overal
mortal
day
day
follow
rsv
lrd
n
n
respect
death
respiratori
failur
observ
n
n
patient
day
day
follow
rsv
lrd
respect
unadjust
model
patient
receiv
aerosol
ribavirin
treatment
improv
surviv
compar
receiv
ribavirin
treatment
lrd
vs
overal
death
vs
pulmonari
death
p
supplementari
figur
surviv
curv
stratifi
patient
receiv
oxygen
therapi
lrd
diagnosi
patient
receiv
none
system
ribavirin
shown
supplementari
figur
univari
analysi
day
follow
rsv
lrd
reveal
sever
factor
statist
significantli
associ
overal
mortal
pulmonari
death
includ
transplant
year
cell
sourc
condit
regimen
wbc
count
monocyt
count
platelet
count
oxygen
requir
diagnosi
steroid
use
diagnosi
palivizumab
treatment
ribavirin
treatment
follow
lrd
supplementari
tabl
treatment
aerosol
ribavirin
show
protect
effect
mortal
day
multipl
model
adjust
cell
sourc
oxygen
requir
diagnosi
wbc
count
presenc
copathogen
tabl
protect
effect
figur
hazard
ratio
confid
interv
multivari
model
evalu
respiratori
syncyti
viru
rsv
rna
detect
blood
risk
factor
overal
mortal
pulmonari
death
day
follow
rsv
lower
respiratori
diseas
lrd
n
includ
p
valu
hazard
ratio
p
valu
shown
rsv
rna
detect
model
outcom
day
follow
rsv
lrd
similarli
show
rsv
rna
detect
risk
factor
overal
mortal
pulmonari
death
data
shown
model
includ
presenc
rsv
rna
ribavirin
treatment
plu
covari
b
model
includ
presenc
rsv
rna
median
log
copiesml
ribavirin
treatment
plu
covari
abbrevi
wbc
white
blood
cell
aerosol
ribavirin
also
demonstr
multivari
model
determin
risk
pulmonari
death
tabl
demonstr
sever
host
transplant
virolog
treatment
factor
associ
increas
overal
pulmonari
death
hct
recipi
rsv
lrd
particular
shown
presenc
rsv
rna
blood
signific
proport
patient
rsv
lrd
correl
rsv
rna
detect
mortal
multivari
model
addit
shown
protect
effect
aerosol
ribavirin
overal
pulmonari
mortal
multivari
model
risk
factor
rsv
rna
detect
blood
includ
mechan
ventil
suggest
acut
lung
injuri
play
role
pathogenesi
rsv
infect
possibl
dissemin
viral
nucleic
acid
bloodstream
hypothesi
also
support
associ
thrombocytopenia
rsv
rna
detect
well
associ
higher
bal
viral
load
serum
rsv
rna
detect
risk
factor
rsv
rna
detect
plasmaserum
includ
neutropenia
monocytopenia
impli
inflammatori
respons
play
part
viral
contain
within
respiratori
system
patholog
examin
autopsi
specimen
shown
alveolar
mononuclear
cell
infiltr
children
rsv
bal
specimen
children
rsv
bronchiol
shown
neutrophil
compris
inflammatori
cell
infiltr
height
clinic
symptom
furthermor
rsv
nucleic
acid
demonstr
monocyt
neutrophil
bal
blood
specimen
adult
children
rsv
infect
interestingli
studi
show
substanti
effect
lymphopenia
steroid
use
mgkg
rsv
rna
detect
indic
moder
immun
suppress
impact
blood
rsv
rna
detect
higher
rate
serum
rsv
rna
detect
studi
compar
previou
report
group
may
explain
duplic
extract
rtpcr
test
although
duplic
test
clinic
practic
method
perform
maxim
detect
viral
load
near
limit
detect
approxim
log
copiesml
account
stochast
distribut
patient
duplic
posit
sampl
higher
viral
load
patient
viral
load
median
increas
risk
death
compar
patient
viral
load
median
oral
dose
load
dose
mgkg
follow
mg
everi
hour
day
mg
everi
hour
day
b
current
practic
guidelin
center
involv
treatment
aerosol
ribavirin
patient
rsv
lrd
dose
g
singl
dose
hour
g
three
time
day
hour
c
includ
requir
continu
posit
airway
pressur
mechan
ventil
detect
rsv
rna
serum
plasma
associ
increas
risk
overal
death
multivari
model
well
decreas
time
aliv
hospit
serum
rsv
rna
detect
associ
mortal
hospit
suggest
role
viral
dissemin
diseas
sever
howev
studi
directli
investig
viral
replic
outsid
respiratori
tract
futur
studi
examin
messeng
rna
peripher
blood
sampl
determin
true
virem
phase
occur
sever
rsv
infect
studi
allow
us
evalu
sever
clinic
factor
univari
multivari
analysi
factor
associ
increas
mortal
includ
use
oxygen
diagnosi
receipt
bone
marrow
cord
blood
transplant
steroid
use
mg
kg
prior
diagnosi
leukopenia
presenc
copathogen
supplementari
tabl
addit
interest
effect
ribavirin
clinic
outcom
demonstr
treatment
rsv
lrd
aerosol
ribavirin
hct
recipi
consist
associ
decreas
probabl
overal
death
death
due
respiratori
failur
multivari
model
although
result
suggest
stronger
protect
effect
aerosol
ribavirin
system
ribavirin
supplementari
figur
number
patient
receiv
system
ribavirin
cohort
small
n
therefor
result
interpret
cautious
ribavirin
avail
treatment
rsv
infect
year
use
hct
recipi
controversi
due
low
qualiti
evid
support
use
treatment
rsv
lrd
ribavirin
never
evalu
random
trial
howev
mani
center
administ
ribavirin
without
pool
ivig
rsvspecif
immunoglobulin
palivizumab
pool
analysi
shah
chemali
suggest
hct
recipi
treat
ribavirin
without
immunomodul
lower
rate
mortal
review
separ
studi
studi
first
analysi
singl
cohort
show
protect
effect
ribavirin
overal
pulmonari
mortal
hct
recipi
use
multivari
model
data
also
show
patient
requir
oxygen
therapi
treat
ribavirin
die
hct
recipi
rsv
transplant
earlier
studi
wors
outcom
recent
patient
may
explain
improv
support
care
chang
transplant
practic
recent
year
suggest
earlier
patient
experienc
acut
lung
injuri
relat
rsv
lrd
similarli
patient
requir
increas
oxygen
support
time
lrd
diagnosi
like
die
oxygen
use
may
serv
marker
extent
lung
injuri
associ
poor
outcom
confirm
previou
find
patient
receiv
peripher
blood
stem
cell
transplant
improv
surviv
compar
patient
receiv
bone
marrow
cord
blood
transplant
suggest
import
role
immun
reconstitut
oral
dose
load
dose
mgkg
follow
mg
everi
hour
day
mg
everi
hour
day
b
current
practic
guidelin
center
involv
treatment
aerosol
ribavirin
patient
rsv
lrd
dose
g
singl
dose
hour
g
three
time
day
hour
c
includ
requir
continu
posit
airway
pressur
mechan
ventil
sever
factor
significantli
associ
mortal
notabl
steroid
therapi
mgkgday
time
diagnosi
given
treatment
gvhd
correl
increas
risk
overal
pulmonari
death
although
palivizumab
treatment
protect
univari
model
like
due
inclus
earlier
patient
receiv
neither
ribavirin
palivizumab
therapi
palivizumab
protect
multivari
model
find
recent
analyz
separ
homogen
cohort
patient
receiv
aerosol
ribavirin
interestingli
although
lymphopenia
suggest
risk
factor
progress
urd
lrd
find
lymphopenia
associ
increas
risk
death
patient
establish
rsv
pneumonia
low
total
wbc
count
correl
increas
risk
death
multivari
analys
monocytopenia
correl
increas
death
univari
analysi
find
suggest
role
immun
respons
diseas
sever
limit
studi
includ
retrospect
design
lack
random
evalu
ribavirin
effect
studi
period
long
chang
support
care
practic
account
includ
time
transplantrel
chang
model
rel
small
number
patient
meet
clinic
endpoint
limit
abil
establish
singl
model
account
covari
howev
separ
multivari
model
show
protect
effect
ribavirin
impact
serumplasma
rsv
rna
detect
overal
pulmonari
death
adjust
import
covari
rna
degrad
may
play
role
observ
differ
detect
level
time
studi
test
serum
plasma
wherea
studi
recov
rsv
rna
whole
blood
peripher
blood
monocyt
neutrophil
current
prospect
sampl
collect
way
specif
evalu
addit
cellular
compart
presenc
rsv
genom
rna
rsv
messeng
rna
conclus
data
demonstr
protect
effect
ribavirin
overal
mortal
pulmonari
death
day
day
follow
rsv
lrd
hct
recipi
multivari
model
detect
rsv
rna
blood
associ
increas
risk
death
among
hct
recipi
rsv
lrd
suggest
rsv
rna
detect
blood
may
serv
biomark
poor
overal
outcom
may
indic
need
aggress
therapi
popul
supplementari
materi
avail
clinic
infecti
diseas
onlin
http
cidoxfordjournalsorg
supplementari
materi
consist
data
provid
author
publish
benefit
reader
post
materi
copyedit
content
supplementari
data
sole
respons
author
question
messag
regard
error
address
author
